Table 3.
Univariate and multivariate Cox-regression analysis of overall survival.
| Overall survival | Progression free survival | |||||
|---|---|---|---|---|---|---|
| Parameter | HR | 95% CI | p | HR | 95% CI | p |
| UNIVARIATE ANALYSIS | ||||||
| SBRT vs. TACE | 1.716 | 0.739–3.985 | 0.21 | 2.172 | 0.988–4.775 | 0.05 |
| Child pugh score (7–9 vs. 5–6) | 3.968 | 1.419–11.096 | 0.01 | 1.831 | 0.689–4.864 | 0.23 |
| ALBI grade (2–3 vs. 1) | 1.677 | 0.724–3.587 | 0.23 | 1.181 | 0.551–2.531 | 0.67 |
| nodules (multiple vs. solitary) | 1.530 | 0.653–3.587 | 0.33 | 2.759 | 1.207–6.306 | 0.02 |
| Prior treatments (yes vs. no) | 1.286 | 0.554–2.982 | 0.56 | 2.693 | 1.199–6.046 | 0.02 |
| Metastases (yes vs. no) | 1.728 | 0.499–5.980 | 0.39 | 2.260 | 0.634–8.052 | 0.21 |
| Diameter ≥ 50 mm (yes vs. no) | 3.214 | 1.355–7.624 | 0.01 | 1.740 | 0.782–3.873 | 0.18 |
| BCLC (A vs. C) | 0.514 | 0.161–1.638 | 0.26 | 0.208 | 0.055–0.787 | 0.02 |
| BCLC (B vs. C) | 0.478 | 0.177–1.289 | 0.15 | 0.471 | 0.197–1.126 | 0.09 |
| Portal vein thrombosis (yes vs. no) | 1.454 | 0.626–3.374 | 0.03 | 2.341 | 0.919–5.965 | 0.07 |
| MULTIVARIATE ANALYSIS | ||||||
| SBRT vs. TACE | 1.948 | 0.778–4.879 | 0.15 | 2.855 | 1.227–6.644 | 0.02 |
| Child pugh score (7–9 vs. 5–6) | 8.866 | 2.355–33.376 | <0.01 | 5.637 | 1.661–19.123 | <0.01 |
| Diameter ≥ 50 mm (yes vs. no) | 4.695 | 1.810–12.177 | <0.01 | |||
| HCC (multiple vs. solitary) | 3.344 | 1.171–9.547 | 0.02 | 5.021 | 1.840–13.699 | <0.01 |
CI, confidence interval; HR, Hazard ratio; TACE, transarterial chemoembolization; SBRT, stereotactic body radiation therapy; ALBI, albumin bilirubin grade; HCC, hepatocellular carcinoma, BCLC, Barcelona liver clinic classification.